Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib
following cellular therapy in treating patients with large B-cell lymphoma at very high risk
of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere
with the ability of cancer cells to grow and spread.